RxDoctor Payments Data

Ruby Ali, MD

Neurology · Fairfield, CANPI 1093990426

Payments from drug & device makers

$19,193in general payments, 2019–2025

Across 862 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Livanova USA, Inc.$3K
  • UCB, Inc.$1K
  • Biogen$965
  • Pfizer$637
  • Johnson & Johnson$561
  • plus $7K from 52 others

What the payments were for

  • Travel & lodging$2,04511%
  • Food & beverage$17,00589%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)276$5,431
Livanova USA, Inc.34$3,366
UCB, Inc.53$1,057
Biogen69$965
Pfizer40$637
Johnson & Johnson(3 entities)29$561
Sanofi25$489
SK Life Science, Inc.21$467
Novartis23$444
Biohaven Pharmaceuticals, Inc.26$382
Teva Pharmaceuticals USA, Inc.15$379
EMD Serono, Inc.18$367
Acadia Pharmaceuticals Inc19$364
Bristol Myers Squibb19$354
Amneal Pharmaceuticals LLC16$320
Amgen(2 entities)14$286
Lilly USA, LLC14$281
Biohaven Pharmaceutical Holding Company Ltd.20$227
Scilex Pharmaceuticals Inc.10$197
Merz Pharmaceuticals, LLC8$192
Takeda Pharmaceuticals U.S.A., Inc.8$185
Argenx US, Inc.8$176
Tanabe Pharma America, Inc.7$168
AstraZeneca7$155
Jazz Pharmaceuticals Inc.5$130
Aucta Pharmaceuticals, Inc.5$120
Banner Life Sciences, LLC5$114
Eisai Inc.5$96
Neurocrine Biosciences, Inc.3$96
GE HealthCare4$93
Genentech USA, Inc.4$81
Lundbeck LLC4$78
Intercept Pharmaceuticals, Inc.4$76
Integra Lifesciences Corporation3$69
MDD US Operations, LLC4$61
Redhill Biopharma Inc.3$59
Adamas Pharmaceuticals, Inc.4$59
Supernus Pharmaceuticals, Inc.3$56
Greenwich Biosciences, Inc.3$54
Axsome Therapeutics, Inc.2$51
Kyowa Kirin, Inc.2$44
Neurelis, Inc.2$38
Neuropace, Inc.1$38
Otsuka America Pharmaceutical, Inc.2$36
ANI Pharmaceuticals, Inc.2$33
Merz North America, Inc.1$27
Promius Pharma LLC1$25
Braintree Laboratories, Inc.1$23
Impel Pharmaceuticals Inc.1$22
TG Therapeutics, Inc.1$21
Baxter Healthcare1$21
Otsuka Pharmaceutical Development & Commercialization, Inc.1$21
CSL Behring1$19
Avanir Pharmaceuticals, Inc.1$18
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$18
Genentech, Inc.1$17
Vertical Pharmaceuticals, LLC1$15
GSK1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,193 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$242,628
Medicare patients
450
Services billed
18,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate69$125,167
QuliptaAtogepant71$78,566
XcopriCenobamate30$52,667
UbrelvyUbrogepant25$33,214
Lacosamide104$26,507
RytaryCarbidopa/Levodopa18$17,160
Emgality PenGalcanezumab-Gnlm22$15,043
VimpatLacosamide11$10,275
Dimethyl Fumarate34$8,988
Emgality SyringeGalcanezumab-Gnlm11$7,504
Levetiracetam172$7,294
Teriflunomide18$3,800
Rasagiline Mesylate13$3,772
Memantine Hcl136$3,662
Divalproex Sodium35$3,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$637$125,16769 claims
AbbVieQulipta, Ubrelvy$5,431$111,78096 claims
SK Life Science, Inc.Xcopri$467$52,66730 claims
Amneal Pharmaceuticals LLCRytary$320$17,16018 claims
UCB, Inc.Vimpat$1,057$10,27511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Fairfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →